Routes of
administration Oral CAS Number 366017-09-6 IUPHAR/BPS 6011 | ATC code none PubChem CID 6444692 Molar mass 468.47 g/mol | |
 | ||
Legal status In general: uncontrolled | ||
Mubritinib tak 165 a potent inhibitor
Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.
References
Mubritinib Wikipedia(Text) CC BY-SA